Hellen Regina Oliveira de Almeida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hellen Regina Oliveira de Almeida has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alice Simon
Laboratory for Drug and Medicine Quality Control (LabCQ), Department of Drugs and Pharmaceutics, Faculty of Pharmacy, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
1 shared publication - Beatriz Ferreira de Carvalho Patricio
Universidade Federal do Estado do Rio de Janeiro (UNIRIO)
1 shared publication - Debora Baptista Pereira
Post-Graduation Program of Chemistry, Federal Rural University of Rio de Janeiro (UFRRJ), Seropédica 23897-000, RJ, Brazil
1 shared publication - Helvécio Vinícius Antunes Rocha
Instituto de Tecnologia de Fármacos, Farmanguinhos, Fundação Oswaldo Cruz, Rio de Janeiro 21040-361, RJ, Brazil
1 shared publication - Lucio Mendes Cabral
Universidade Federal do Rio de Janeiro
1 shared publication - Michelle Alvares Sarcinelli
Laboratório de Micro e Nanotecnologia Farmanguinhos – FIOCRUZ Rio de Janeiro Brazil
1 shared publication
Latest Publications
- Open Access
- 23 May 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (5) , 217
Comparative Study of Rotigotine Release and Permeation from the Neupro® Transdermal Patch: An In Vitro-In Vivo Correlation
Rotigotine (RTG) is a non-ergolinic dopaminergic agonist indicated for Parkinson’s and Willis-Ekbom diseases, administered exclusively via Neupro
- 23 May 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (5) , 217
Open AccessComparative Study of Rotigotine Release and Permeation from the Neupro® Transdermal Patch: An In Vitro-In Vivo Correlation
Rotigotine (RTG) is a non-ergolinic dopaminergic agonist indicated for Parkinson’s and Willis-Ekbom diseases, administered exclusively via Neupro
- 1 May 2021
- Published by Wiley in Journal of Applied Polymer Science
- Vol. 138 (37) , 50944
Production of biodegradable rods of polycaprolactone/olanzapine for potential application in treatment of Schizophrenia
Olanzapine (OLZ) is a commonly antipsychotic used to treat schizophrenia, a mental illness, with fewer side effects when compared with other drugs of the same class. It is commercialized mainly as oral tablets and orally disintegrating tablets. However, this drug oral bioavailability is affected by the first pass effect and low solubility in water. This requires high daily doses that can cause more side effects and poor treatment compliance. Also, the frequency of frequency of tablet intake is commonly related to patients' abandonment of schizophrenia treatment. So, the development of implantable biomaterials for OLZ delivery can be an alternative to solve both problems, since this material can, potentially, be used subcutaneously in less frequent administrations, thus the treatment has a greater chance of success. Therefore, the objective of this work was to produce polycaprolactone (PCL) rods incorporated with OLZ by hot‐melt extrusion technique. The rods were characterized by different techniques, which showed an amount of 6.78 ± 0.56 mg of OLZ per rod. The in vitro release studies were performed and they showed a controlled release of the drug that followed the Higuchi's model. These results indicated that the PCL/OLZ rods have potential application in the schizophrenia treatment.
- 1 May 2021
- Published by Wiley in Journal of Applied Polymer Science
- Vol. 138 (37) , 50944
Production of biodegradable rods of polycaprolactone/olanzapine for potential application in treatment of Schizophrenia
Olanzapine (OLZ) is a commonly antipsychotic used to treat schizophrenia, a mental illness, with fewer side effects when compared with other drugs of the same class. It is commercialized mainly as oral tablets and orally disintegrating tablets. However, this drug oral bioavailability is affected by the first pass effect and low solubility in water. This requires high daily doses that can cause more side effects and poor treatment compliance. Also, the frequency of frequency of tablet intake is commonly related to patients' abandonment of schizophrenia treatment. So, the development of implantable biomaterials for OLZ delivery can be an alternative to solve both problems, since this material can, potentially, be used subcutaneously in less frequent administrations, thus the treatment has a greater chance of success. Therefore, the objective of this work was to produce polycaprolactone (PCL) rods incorporated with OLZ by hot‐melt extrusion technique. The rods were characterized by different techniques, which showed an amount of 6.78 ± 0.56 mg of OLZ per rod. The in vitro release studies were performed and they showed a controlled release of the drug that followed the Higuchi's model. These results indicated that the PCL/OLZ rods have potential application in the schizophrenia treatment.